+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rheumatoid Arthritis (RA) - Pipeline Insight, 2020

  • ID: 4989043
  • Clinical Trials
  • October 2020
  • Region: Global
  • 120 pages
  • DelveInsight

FEATURED COMPANIES

  • Abivax
  • Bristol-Myers Squibb
  • Galapagos
  • Gilead Sciences
  • Oscotec, Yungjin Pharm.
  • SynAct Pharma Aps
  • MORE
This “Rheumatoid Arthritis - Pipeline Insight, 2020” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Rheumatoid Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Rheumatoid Arthritis Understanding

Rheumatoid Arthritis: Overview

Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease, which means that immune system attacks healthy cells in body by mistake, causing inflammation (painful swelling) in the affected parts of the body. Rheumatoid arthritis mainly attacks the joints, usually many joints at once. RA commonly affects joints in the hands, wrists, and knees. In a joint with RA, the lining of the joint becomes inflamed, causing damage to joint tissue. This tissue damage can cause long-lasting or chronic pain, unsteadiness (lack of balance), and deformity (misshapenness). Rheumatoid arthritis can also affect other tissues throughout the body and cause problems in organs such as the lungs, heart, and eyes.

Symptoms

Signs and symptoms of RA include:
  • Pain or aching in more than one joint
  • Stiffness in more than one joint
  • Tenderness and swelling in more than one joint
  • The same symptoms on both sides of the body (such as in both hands or both knees)
  • Weight loss
  • Fever
  • Fatigue or tiredness
  • Weakness
Diagnosis

Rheumatoid Arthritis is diagnosed by reviewing symptoms, conducting a physical examination, and doing X-rays and lab tests. It’s best to diagnose Rheumatoid Arthritis early - within 6 months of the onset of symptoms - so that people with the disease can begin treatment to slow or stop disease progression (for example, damage to joints). Diagnosis and effective treatments, particularly treatment to suppress or control inflammation, can help reduce the damaging effects of Rheumatoid Arthritis.

Treatment

Rheumatoid Arthritis can be effectively treated and managed with medication(s) and self-management strategies. Treatment for Rheumatoid Arthritis usually includes the use of medications that slow disease and prevent joint deformity, called disease-modifying antirheumatic drugs (DMARDs); biological response modifiers (biologicals) are medications that are an effective second-line treatment. In addition to medications, people can manage their Rheumatoid Arthritis with self-management strategies proven to reduce pain and disability, allowing them to pursue the activities important to them.

Rheumatoid Arthritis Emerging Drugs Chapters

This segment of the Rheumatoid Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Rheumatoid Arthritis Emerging Drugs

HB-adMSCs: Hope Biosciences

Hope Bio’s core technology lies in stem cell culture and banking. Mesenchymal stem cells are isolated from approximately one tablespoon of fat tissue, purified, and cultured with Hope Bio’s proprietary culture media, HB-101. HB-adMSCs are expanded to multiple passages and released at Passage 4 for therapeutic use. HB-adMSCs have already been used as a safe and effective treatment in a Phase I/IIa clinical trial for Rheumatoid Arthritis.

ABX464: Abivax

The Phase 2a study, ABX464-301, investigates the safety and tolerability of ABX464 in combination with methotrexate in patients with moderate-to-severe active Rheumatoid Arthritis. Patients enrolled in the study had an inadequate response to methotrexate or/and to one or more anti-tumor necrosis factor alpha (TNFα) therapies.

Rheumatoid Arthritis: Therapeutic Assessment

This segment of the report provides insights about the different Rheumatoid Arthritis drugs segregated based on following parameters that define the scope of the report.

Major Players in Rheumatoid Arthritis

There are approx. 50+ key companies which are developing the therapies for Rheumatoid Arthritis. The companies which have their Rheumatoid Arthritis drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Gilead Sciences, Galapagos NV, Abivax, Viela Bio, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., Oscotec, Yungjin Pharm. Co., Ltd., AbbVie, Aclaris Therapeutics, Inc., Navidea Biopharmaceuticals, Bristol-Myers Squibb, SynAct Pharma Aps etc.

Phases

This report covers around 50+ products under different phases of clinical development like
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Intravenous
  • Oral
  • Intramuscular
  • Subcutaneous
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Small molecules
  • Monoclonal antibodies
  • Stem cell therapies
  • Immunotherapies
  • Peptide vaccines
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Rheumatoid Arthritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rheumatoid Arthritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rheumatoid Arthritis drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Rheumatoid Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Rheumatoid Arthritis.
  • August 2020: Gilead's rheumatoid arthritis medicine filgotinib, after cold shoulder from FDA, wins global-first nod in Japan. The U.S. agency raised concerns about sperm toxicity, especially for the higher, 200-mg dose.
Rheumatoid Arthritis Report Insights
  • Rheumatoid Arthritis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Rheumatoid Arthritis Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Rheumatoid Arthritis drugs?
  • How many Rheumatoid Arthritis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rheumatoid Arthritis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Rheumatoid Arthritis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Rheumatoid Arthritis and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Gilead Sciences
  • Galapagos
  • Abivax
  • Viela Bio
  • Jiangsu Alphamab Biopharmaceuticals Co.
  • Oscotec, Yungjin Pharm.
  • AbbVie, Aclaris Therapeutics
  • Navidea Biopharmaceuticals
  • Bristol-Myers Squibb
  • SynAct Pharma Aps
Key Products
  • HB-adMSCs
  • FURESTEM-RA Inj
  • Autologous adipose derived stem cells
  • ABX464
  • TJ003234
  • Umbilical cord mesenchymal stem cells
  • Ianalumab
  • GCK
  • hUC-MSC suspension
  • VIB4920
  • PF-06650833
  • GB224

This report will be delivered within 2-4 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abivax
  • Bristol-Myers Squibb
  • Galapagos
  • Gilead Sciences
  • Oscotec, Yungjin Pharm.
  • SynAct Pharma Aps
  • MORE
Introduction

Executive Summary

Rheumatoid Arthritis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Rheumatoid Arthritis - Analytical Perspective

In-depth Commercial Assessment
  • Rheumatoid Arthritis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Rheumatoid Arthritis Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Olokizumab: R-Pharm
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
ABX464: Abivax S.A.
  • Product Description
  • Research and Development
  • Product Development Activities
Dazodalibep: Viela Bio
  • Product Description
  • Research and Development
  • Product Development Activities
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
Research programme: Rheumatoid Arthritis Therapeutics: twoXAR
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Rheumatoid Arthritis Key Companies

Rheumatoid Arthritis Key Products

Rheumatoid Arthritis- Unmet Needs

Rheumatoid Arthritis- Market Drivers and Barriers

Rheumatoid Arthritis- Future Perspectives and Conclusion

Rheumatoid Arthritis Analyst Views

Rheumatoid Arthritis Key Companies

Appendix

List of Tables
Table 1 Total Products for Rheumatoid Arthritis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Rheumatoid Arthritis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Gilead Sciences
  • Galapagos
  • Abivax
  • Viela Bio
  • Jiangsu Alphamab Biopharmaceuticals Co.
  • Oscotec, Yungjin Pharm.
  • AbbVie, Aclaris Therapeutics
  • Navidea Biopharmaceuticals
  • Bristol-Myers Squibb
  • SynAct Pharma Aps
Note: Product cover images may vary from those shown
Adroll
adroll